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Abstract
The hyaluronic acid (HA) receptor for endocytosis (HARE; 
also designated stabilin-2 and FEEL-2) mediates systemic 
clearance of glycosaminoglycans from the circulatory and 
lymphatic systems via coated pit-mediated uptake. HARE is 
primarily found as two isoforms (315- and 190-kDa) in sinusoi-
dal endothelial cells of the liver, lymph node, and spleen. Here 
we characterize the ligand specificity and function of the large 
stably expressed 315-HARE isoform in Flp-In 293 cell lines. 
Like human spleen sinusoidal endothelial cells, Flp-In 293 cell 
lines transfected with a single cDNA encoding the full-length 
315-HARE express both the 315-kDa and the proteolytically 
truncated 190-kDa isoforms in a ratio of ~3–4:1. The 190-
kDa HARE isoform generated from the 315-kDa HARE and 
the 315-kDa HARE specifically bound 125I-HA. Like the 190-
kDa HARE expressed alone (Harris, E. N., Weigel, J. A., and 
Weigel, P. H. (2004) J. Biol. Chem. 279, 36201–36209), the 
190- and 315-kDa HARE isoforms expressed in 315-HARE 
cell lines were recognized by anti-HARE monoclonal antibod-
ies 30, 154, and 159. All 315-HARE cell lines could endocy-
tose and degrade 125I-HA. Competition studies with live cells 
indicate that 190-HARE and 315-HARE bind HA with higher 
apparent affinity (Kd ~10–20 nm) than chondroitin sulfate (CS) 
types A, C, D, or E. Only slight competition of HA endocyto-
sis was observed with CS-B (dermatan sulfate) and chondroi-
tin. Direct binding assays with the 315-HARE ectodomain re-
vealed high affinity HA binding, and lower binding affinities for 
CS-C, CS-D, and CS-E. A majority of each HARE isoform was 
intracellular, within the endocytic system, suggesting tran-
sient surface residency typical of an active endocytic recycling 
receptor. 
Abbreviations: GAG, glycosaminoglycan; BSA, bovine serum albu-
min; CS, chondroitin sulfate; CS-A, chondroitin 4-sulfate; CS-C, chon-
droitin 6-sulfate; CS-D, chondroitin 2,6-sulfate; CS-E, chondroitin 
4,6-sulfate; ECM, extracellular matrix; HA, hyaluronic acid, hyaluro-
nate, hyaluronan; HARE, HA receptor for endocytosis; hHARE, hu-
man HARE; HBSS, Hanks’ balanced salts solution; HS, heparan sul-
fate; mAb, monoclonal antibody; PBS, phosphate-buffered saline; 
s190-HARE, soluble 190-kDa HARE ectodomain; s315-HARE, solu-
ble ectodomain of the 315-kDa HARE; 190-HARE, the 190-kDa HA 
receptor for endocytosis; 315-HARE, the 315-kDa HA receptor for 
endocytosis; s190- and s315-HARE, soluble 190- and 315-HARE, re-
spectively; ELISA, enzyme-linked immunosorbent assay; DMEM, Dul-
becco’s modified Eagle’s medium; FBS, fetal bovine serum
The glycosaminoglycan (GAG) hyaluronic acid (HA) is a pro-
tein-free polymer of disaccharide units containing glucuronic 
acid and N-acetylglucosamine (1, 2). HA is involved in many 
physiological processes (3), such as wound healing, develop-
ment, and metastasis of some cancers (4–8). The typical molec-
ular mass of the polysaccharide ranges from just a few thou-
sand Da (tens of sugars) that are thought to be important in 
cellular signaling (6) to several million Da (tens of thousands 
of sugars). These larger forms of HA are present throughout 
the body and are particularly concentrated within the bursa 
of major joints, such as the knee, where they help to provide 
shock absorbance in cartilage or lubrication in synovial fluid 
(9, 10), and the eye, where HA maintains structural integ-
rity of the vitreous humor (11). The adult human body con-
tains ~15g of HA, of which about 5 g are turned over daily 
(12). Partially degraded HA perfuses from extracellular matri-
ces (ECMs) and enters the lymphatic and vascular circulation 
systems, where it is catabolized to shorter fragments. This ac-
tive maintenance of HA turnover must be efficient in order to 
maintain homeostatic conditions for total body HA. 
All of the other GAGs, including the chondroitin sulfates 
(CSs), heparan sulfate (HS), and keratan sulfate, are linked 
to core proteins (as proteoglycans) that help to form ECMs, 
such as the basement membranes of tissues, or structural 
components of organs, such as the vitreous humor. There are 
over 30 known core proteins that are essential for a diverse 
array of functions, such as neural development, growth fac-
tor signaling, and pathogen recognition (13). These core pro-
teins are found as prevalent components of tissue ECMs or 
as specialized components needed for the development of 
microenvironments that interface a specialized tissue cell 
type with the ECM. Both the proteoglycans and their at-
tached GAG chains may combinatorially interact with li-
gands and contribute to modulation of the functional as-
pects of a particular microenvironment (e.g. CS interacting 
with apolipoprotein E for uptake of β-very low density lipo-
protein in hippocampal neurons) (14). Although numerous 
studies have focused on how the inhibition of some CS pro-
teoglycans enhances neural development, especially in in-
jured spinal cord models, there is very little information on 
how CS and HS are catabolized. The current model is that 
extracellular chondroitinases, heparinases, and proteases ini-
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tially break down these GAGs and proteoglycans, and their 
final digestion can then take place intracellularly at the local 
tissue level. However, in many cases, some of these GAGs 
and proteoglycan fragments will probably find their way 
into the lymphatic and circulatory systems, especially dur-
ing injury or disease. Without some type of efficient GAG-
clearing mechanism, these fluid circulatory systems may get 
overwhelmed with large amounts of debris derived from tis-
sue ECMs throughout the body. 
Although the synthesis and catabolism of HA are generally 
the most understood pathways of any of the GAGs, the de-
tails of each pathway currently remain largely unknown. In 
the early 1980s, it was observed that liver sinusoidal endothe-
lial cells endocytose circulating HA (15–19). We know now 
that HA·HARE complexes are endocytosed via the clathrin-
coated pit pathway (20, 21), and their formation is cation-in-
dependent (22), specific, and of high affinity (23, 24). Like the 
mannose, low density lipoprotein, and asialoglycoprotein re-
ceptors, HARE is a recycling receptor that moves through 
an intracellular itinerary every ~10–15 min (25). This recep-
tor system was shown to be responsible for the physiological 
turnover of about one-third of the total body HA per day (12, 
26). Most of the partially degraded HA perfusing from a tis-
sue ECM encounters this HA receptor first in lymph nodes, 
which catabolize about 85% of the HA turning over daily. The 
remaining 15% of the HA drains from the lymphatics into the 
circulatory system and is removed by the same receptors pres-
ent in liver sinusoidal endothelium. This rapidly recycling HA 
receptor is also present in high copy number in spleen, where 
it presumably mediates additional, but unknown, HA/GAG 
activities other than systemic clearance. 
The primary scavenger receptor for systemic HA turn-
over is HARE. Orthologues of this receptor are present in 
other mammals, including cow, pig, guinea pig, rat, mouse, 
and human (27). Human and rat HARE are primarily found 
in the sinusoidal endothelial cells of the lymph nodes, liver, 
and spleen (28–31). Additionally, mouse HARE/Stab-2 has 
been detected in specialized tissues, such as the corneal and 
lens epithelium, mesenchymal cells of heart valves, and pris-
matic epithelial cells covering the renal papillae (27), and bo-
vine HARE has been reported in the oviduct (32). 
The HARE proteins were first purified from rat liver (33) 
and human spleen (30) and then molecularly cloned from rat 
and human RNA pools (29–31). The hHARE is encoded by 
a single gene found on chromosome 12q23.3 spanning 180.2 
kb and containing 69 exons. The gene encodes a 2551-amino 
acid glycoprotein with a molecular mass of ~315 kDa in SDS-
PAGE. A primary function of this receptor is to bind and in-
ternalize HA for turnover, although other GAGs, such as the 
CSs (20, 34–37) (this report) are also internalized by this re-
ceptor, and advanced glycation end products appear to be 
ligands as well (38, 39). The internalized receptor traffics 
through the early endocytic pathway and is recycled to the 
cell surface (21, 29, 37, 39). A 20-min recycling time was ob-
served for the rat 175-kDa HARE expressed in SK-Hep1 cell 
lines, whereas a 7–9-min cycle rate was observed with the 
190-kDa hHARE expressed in Flp-In 293 cells. These incon-
sistent receptor recycling times may be dependent on intrin-
sic cell machinery differences. 
Although our group has studied the biological activity 
of rat and human HARE, we have focused primarily on the 
smaller 190-kDa HARE isoform. Other groups have focused 
on the full-length HARE in human, mouse, pig, and cattle and 
overlooked the smaller isoform as a breakdown product or an 
experimental anomaly. Thus, confusion has arisen about this 
particular receptor, including the existence of the smaller form 
(175 kDa in rat, 190 kDa in human), where it comes from, 
whether it is functional, and, if so, what the biological implica-
tions may be (40, 41). For example, the ratio of rat 175-HARE 
to 300-HARE in the liver is higher than in the spleen. Thus, the 
levels of each isoform appear highly regulated (30, 33), but it 
is still not known why or how this occurs. We recently con-
firmed that the 190-kDa hHARE is, in fact, a functional endo-
cytic recycling receptor that can mediate GAG uptake in the 
absence of the larger 315-kDa hHARE (37). 
In this report, we stably expressed the recombinant full-
length 315-kDa human HARE, using cDNA derived from 
human lymph node, and show that a small fraction of the 
total parent receptor is proteolytically cleaved to produce a 
functional 190-kDa receptor. Thus, the 315-HARE expressed 
in stable Flp-In 293 cell lines produces two receptors that 
bind to and internalize HA. The secreted ectodomain of the 
315-kDa receptor was glycosylated; was reactive with anti-
HARE monoclonal antibodies (mAbs); bound HA, CS-C, 
CS-D, and CS-E well; and bound more weakly to CS-B and 
chondroitin. When expressed in Flp-In 293 cells, most of the 
receptors are found intracellularly, suggesting that as the re-
ceptor cycles between plasma membrane and endocytic vesi-
cles, the time spent on the surface is quite short. 
Experimental Procedures
Materials, Solutions, and Buffers—Tris-HCl, glycine, and 
acrylamide were obtained from Research Products Interna-
tional (Mt. Prospect, IL); MgCl2, SDS, and methanol were 
from EMD (Gibbstown, NJ); Triton X-100, o-nitrophenyl-β-
d-galactoside, digitonin, Tween 20, saponin, cetylpyridin-
ium chloride, secondary antibodies conjugated to alkaline 
phosphatase, heparin, ampicillin, and imidazole were ob-
tained from Sigma. Formaldehyde without methanol for cell 
fixation was from Polysciences, Inc. (Warrington, PA). All 
GAGs except HA and heparin were from Seikagaku Corp. 
(Tokyo, Japan) and characterized by size exclusion chroma-
tography/multiangle laser light scattering. HA, prepared 
from bacterial fermentation, was obtained from Genzyme 
Corp. (Cambridge, MA). Flp-In 293 cells, serum, DMEM, hy-
gromycin B, zeocin, glutamine, plasmid expression vectors, 
supercompetent TOP10 Escherichia coli, and Lipofectamine 
2000 were from Invitrogen. Anhydrous Me2SO and CuCl2 
were obtained from Acros Chemical (Morris Plains, NJ). 125I 
(100 mCi/ml; specific activity of >0.6 TBq/mg) in NaOH 
and Sepharose 6 Fast Flow (nickel-nitrilotriacetic acid) resin 
were from Amersham Biosciences. 125I-HA and 125I-streptav-
idin were prepared as described previously (42, 43). Strepta-
vidin, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl, 
biotin-LC-hydrazide, and sulfo-NHS-SS-biotin were pur-
chased from Pierce. p-Nitrophenyl phosphate reagent was 
from Kirkegaard & Perry Laboratories, Inc. (Gaithersburg, 
MD), and ELISA strips were from Nunc (Roskilde, Den-
mark). Affinity-purified polyclonal goat anti-V5 antibody 
and goat anti-V5 antibody resin were obtained from Bethyl 
Laboratories (Montgomery, TX). Affinity-purified anti-V5 
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mAb was from Serotec (Oxford, UK). Anti-actin mAb (I-19) 
and Protein A/G Plusagarose were from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA). Taq polymerase for DNA end 
modifications and screening was from Continental Labora-
tory Products (San Diego, CA), and pfu Ultra for cloning was 
from Stratagene (La Jolla, CA). We purified DNA from aga-
rose or aqueous solutions using Qbiogene Bio 101 DNA pu-
rification kits (Carlsbad, CA). We used either colorimetric 
or chemiluminescence detection of blotted protein for West-
ern blot analysis. Colorimetric reagents (p-nitro blue tetra-
zolium and sodium 5-bromo-4-chloro-3-indolyl phosphate 
p-toluidine) and the chemiluminescence reagents (Luminol 
and peroxide solutions) were from Pierce. Concentrator/de-
salting cartridges were from Amicon (Bedford, MA). TBST 
contains 20 mm Tris-HCl, pH 7.0, 150 mm NaCl, and 0.1% 
Tween 20. TBST/BSA is TBST with 1.0% (w/v) BSA. Coat-
ing Buffer for ELISA assays contains 15 mm Na2CO3, 36 mm 
NaHCO3, pH 9.5. HBSS contains 5 mm KCl, 0.4 mm KH2PO4, 
0.8 mm MgSO4, 137 mm NaCl, 0.3 mm Na2HPO4, 5.5 mm 
glucose, 1.26 mm CaCl2, 0.5 mm MgCl2, and 28 μm phenol 
red. At the time of use, 3.5 g/100 ml of NaHCO3 was added, 
and the pH was adjusted to 7.0 with HCl. Z-buffer for the 
β-galactosidase activity assay contains 60 mm Na2HPO4, 40 
mm NaH2PO4, 10 mm KCl, 1.0 mm MgSO4, 50 mm 2-mer-
captoethanol, pH 7.0. 
Construction of the 315-HARE Expression Vector—Due to 
the large size of the cDNA, the 315-kDa hHARE coding re-
gion was amplified from lymph node cDNA pools (Mara-
thon System; BD Biosciences) using pfu Ultra in two sections 
that overlapped by 484 nucleotides. The 5′-half of the cDNA 
was amplified using gene-specific forward (5′-GGATC-
CATGATGCTACAACATTTAGTAATTTTTTGTCTTGG-3′) 
and reverse (5′-GGTCATTATGGAGAAAGAAGCTCAG-
GAAATAGGAG-3′) primers, whereas the 3′-half of the 
cDNA was amplified using gene-specific forward (5′-TCCT-
TACCAAACCTGCTCATGCGGCTGGAACAG-3′) and re-
verse (5′-GGATCCCAGTGTCCTCAAGGGGTCATTGCC-3′) 
primers. Both cDNA sections were purified, mixed, dena-
tured, and allowed to hybridize together, and the comple-
mentary strands were filled in using pfu Ultra. Using the for-
ward primer for the 5′-half and the reverse primer for the 
3′-half, we then amplified the entire 315-HARE encoding 
cDNA (35 cycles, Tm = 55 °C, extension time = 8 min). Im-
mediately following the amplification, 2.5 units of Taq poly-
merase and 2 mm MgCl2 were added to the reaction mixture, 
which was incubated for 10 min at 72 °C to add free deoxy-
adenylate on the 3′-ends of the PCR product for compati-
ble cloning in the TOPO line of expression vectors. The PCR 
product representing the full-length 315-HARE cDNA was 
purified by agarose gel electrophoresis using a 0.8% (w/v) 
gel containing 0.002% crystal violet for band visualization. 
The band was excised with a clean razor blade, gene-cleaned, 
ligated into pcDNA5/FRT/V5/His6-TOPO, and trans-
formed into TOP10 E. coli cells. Colonies growing on LB-am-
picillin plates were screened for cDNA inserts by visualizing 
total extracted nucleic acid on 1% agarose gels stained with 
ethidium bromide. Colonies with potential HARE cDNA 
were verified by PCR using gene-specific forward (5′-GTTC-
CATCTACGATCGCCACTGGGCCAG-3′) and vector-spe-
cific reverse (5′-CGTAGAATCGAGACCGAGGAG-3′) prim-
ers. The complete sequences of the promoter and complete 
coding regions of cDNAs in the final clones were determined 
to be correct before they were used in subsequent experi-
ments. This full-length HARE DNA sequence obtained was 
identical to that of NCBI accession entry NM_017564 with 
the exception of silent mutations located at codons 833, 1112, 
1700, 1937, 2005, and 2175 and one missense mutation, which 
created a D1276A mutation. However, Ala1276 was reported 
in an earlier entry for stabilin-2 (accession number AJ295695) 
and was also present in the 190 hHARE clones reported by 
Harris et al. (37). The D1276A change does not appear to af-
fect the biological activity of the receptor and probably rep-
resents a polymorphism in the human STAB2 gene. All pro-
tein expression experiments were performed using this 
NM_017564-like cDNA. 
Selection and Verification of 315-hHARE Cell Lines—Cell 
lines were produced and characterized as described by Har-
ris et al. (37) with minor modifications. Flp-In 293 cells (3 × 
106; Invitrogen) were plated in a 100-mm dish 2 days prior 
to transfection. Cells incubating in 10 ml of fresh antibiotic-
free DMEM supplemented with 8% fetal bovine serum were 
transfected by the addition of 750 μl of serum-free DMEM 
containing 1.0 μg of pcDNA5/FRT/315-HARE V5/His6, 
9.0 μg of pOG44 (encoding the Flp-In recombinase) and 20 
μl of Lipofectamine 2000. Starting 24–36 h post-transfection, 
the medium was replaced every 2–3 days with DMEM plus 
8% FBS containing 100 μg/ml hygromycin B. Visible circular 
colonies were present about 2 weeks post-transfection and 
isolated using a P20 pipette with P200 tips. About 40 colo-
nies were isolated by gently nudging with the tip while as-
pirating no more than 10 μl at a time. Medium on the plate 
was changed after picking every five colonies to reduce the 
chance of aspirating free-floating cells. Isolated colonies 
were grown in 24-well dishes in DMEM plus 8% FBS with 
100 μg/ml hygromycin B. After a monolayer of cells had de-
veloped from each clone, cells were scraped in 1 ml of me-
dium and partitioned into four portions. One portion (100 
μl) was reseeded in fresh medium and allowed to continue 
growing in the 24-well dish. The second portion (100 μl) was 
reseeded in 100 μg/ml zeocin to test for zeocin sensitivity. 
The third portion (400 μl) was pelleted and resuspended in 
50 μl of 4× Laemmli sample buffer (44) to test for HARE ex-
pression by SDS-PAGE followed by Western analysis using 
anti-V5 antibody. 
The remaining 400 μl of cell suspension was pelleted and 
assayed for β-galactosidase activity. In addition to the zeo-
cin sensitivity test, the β-galactosidase test indicates whether 
the HARE-encoding plasmid integrated specifically and cor-
rectly into the genomic FRT site, which is the unique fea-
ture of the Flp-In cell line series. The cell pellet for this as-
say was resuspended in 200 μl of PBS containing 0.5% Triton 
X-100 and 20 μl of cell lysate per well of a 96-well plate was 
combined with 70 μl of Z-buffer and 20 μl of 4.0 mg/ml 
o-nitrophenyl-β-d-galactoside in Z-buffer. After 15–30 min at 
37 °C, the absorbance values were measured at 405–420 nm. 
Lysates from HEK Flp-In 293 and HEK 293 cells were used 
as positive and negative controls, respectively. Stable cell 
lines were selected for further study only if they grew well in 
DMEM containing 8% FBS and 100 μg/ml hygromycin B and 
showed HARE expression, hygromycin B resistance, zeocin 
sensitivity, no β-galactosidase activity, and normal cell mor-
phology as determined by phase-contrast microscopy. 
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Endocytosis and Degradation of 125I-HA—The C-termi-
nal epitope tags do not interfere with HA binding, internal-
ization, or trafficking mediated by the 190-kDa HARE (37). 
Stably transfected cell lines expressing the 315-HARE were 
plated in 12-well dishes and allowed to grow in DMEM with 
8% fetal calf serum supplemented with 100 μg/ml hygro-
mycin B at least 2 days prior to an experiment. Cells were 
washed with HBSS and incubated for 60 min with fresh me-
dium containing 0.075% BSA to allow HARE-mediated inter-
nalization of any serum GAGs that might be bound to the 
cell surface. The same DMEM-BSA medium containing 1–2 
μg/ml 125I-HA was then incubated with cells with or with-
out the noted GAG as a competitor. Endocytosis or bind-
ing only of 125I-HA was measured by incubating cells at 37 
or 4 °C, respectively. To determine HA binding by the to-
tal cell receptor population, cells on ice were permeabilized 
with 0.055% (w/v) digitonin (using a 25% stock solution) 
dissolved in anhydrous Me2SO (45). At the indicated times, 
cells were washed three times with ice-cold HBSS and lysed 
in 0.3 n NaOH, and radioactivity and protein content (46) 
were determined. 
Degradation of 125I-HA was measured by a cetylpyri-
dinium chloride precipitation assay, as reported previously 
(47). Briefly, 50 μl of sample medium was mixed with 0.25 
ml of a 1.0 mg/ml solution of HA (as a carrier) in 1.5-ml mi-
crocentrifuge tubes. Alternatively, 100-μl samples of cell ly-
sates in 0.3 n NaOH were mixed with 47 μl of 0.6 n HCl, 28 
μl of distilled water, and 125 μl of 2.0 mg/ml carrier HA so-
lution. After mixing at room temperature, 300 μl of 6% (w/v) 
cetylpyridinium chloride in distilled water was added to 
each tube and vortexed. The samples were allowed to pre-
cipitate for 10 min, followed by centrifugation at 8600 × g 
for 5 min in an Eppendorf 5417 using a swinging bucket ro-
tor. A 300-μl sample of the supernatant was taken for radio-
activity determination, and the remaining supernatant was 
removed by aspiration. The bottoms of the tubes contain-
ing the pellet were cut off and placed in 12 × 75-mm plastic 
tubes for radioactivity determination using a Packard Cobra 
II γ counter. Degradation was calculated as the time-depen-
dent increase of nonprecipitable radioactivity. At least 80% 
of the total radioactivity was precipitable at the beginning of 
each experiment. 
Western and Ligand Blot Assays—Cell lysates or immuno-
precipitates were mixed with 4× Laemmli sample buffer (44) 
without reducing agent and analyzed by SDS-PAGE using 
a 5% gel. Protein electrotransfers to nitrocellulose were per-
formed using a Bandit Electroblotter (Owl Scientific; Roches-
ter, NY) for 1.5 h at 4 °C at 110 constant V in 25 mm Tris, 192 
mm glycine, pH 8.3, and 15% methanol, pH 8.3. Subsequent 
steps were at room temperature. For Western analysis (48), 
the nitrocellulose membranes were treated with TBST/BSA 
for at least 2 h to block nonspecific binding sites followed by 
incubation in TBST/BSA with 1 μg/ml anti-rat HARE mAb 
or 1:5000 anti-V5 antibody. After washing three times with 
TBST, the blots were incubated with the appropriate second-
ary antibody conjugated with alkaline phosphatase or horse-
radish peroxidase, followed by three washes, and then de-
tection with the appropriate reagents. When necessary, the 
blots were stripped of bound antibodies by incubating the 
membranes in 100 mm 2-mercaptoethanol, 2% SDS, 62.5 mm 
Tris-HCl, pH 6.7, at 55 °C for 30 min. After several washes in 
TBST, the blots were reprobed with anti-V5 mAb. Densitom-
etry was performed using an Fluor-Chem 8000 gel visualiza-
tion and analysis system (Alpha Innotech Corp., San Lean-
dro, CA). 
For 125I-HA ligand blots (49), the nitrocellulose membrane 
was incubated with TBST for at least 2 h at 4°C followed by 
an incubation with 1 μg/ml 125I-HA in PBS containing 150 
mm NaCl, 10 mm HEPES, pH 7.4, 5 mm EDTA, with or with-
out 100 μg/ml unlabeled HA as competitor to assess nonspe-
cific binding. Following a 2-h binding incubation at 4 °C, the 
membrane was washed with excess TBST at least five times 
over 30 min and dried at room temperature. Bound 125I-HA 
was detected by autoradiography using Eastman Kodak Co. 
MS film exposed at –80 °C for 24–48 h. 
The method for biotin-GAG ligand blots was a modifi-
cation of the above HA ligand blot procedure in which the 
membrane with blotted proteins was incubated with a spe-
cific amount of biotin-GAG, washed, and detected with 125I-
streptavidin. Biotin-GAGs were made according to the pro-
tocol of Yu and Toole (50), and a biotin quantification kit 
(Vector Laboratories, Burlingame, CA) was used to deter-
mine the number of biotins/GAG chain. The molar mass and 
concentration of each GAG were determined by size exclu-
sion multiangle laser light scattering before and after the bi-
otinylation reactions to ensure the addition of 1–2 biotins per 
GAG chain, without GAG degradation, and to calculate the 
final yield of each biotin-GAG. 
Endoglycosidase F Treatment and Immunoprecipitation—
HARE was immunoprecipitated from cell lysates or media 
containing 0.5% Nonidet P-40 and protease inhibitors (1 μg/
ml leupeptin, 1 μg/ml pepstatin A, 30 μg/ml phenylmeth-
ylsulfonyl fluoride) using anti-rat HARE mAbs 30, 154, and 
159 attached to CNBr-activated Sepharose (0.3 mg/ml each 
mAb) and allowed to rotate overnight at 4 °C. If the sam-
ple was to go straight to Western analysis, the resin was 
washed twice with PBS and eluted with an equal volume of 
4× Laemmli buffer and centrifuged briefly to pellet the resin. 
If the sample was to be treated with endoglycosidase F, the 
centrifuged resin was washed twice with PBS and incubated 
with an equal volume of PBS containing 1% SDS to disrupt 
antibody-HARE binding. The supernatant recovered after 
centrifugation was adjusted to 1% Nonidet P-40 and incu-
bated with 1.0 unit of N-glycosidase F (Roche Applied Sci-
ence) overnight at 37 °C. The sample was then mixed with 
0.25 volumes of 4× Laemmli buffer, separated by 5% SDS-
PAGE, and analyzed by Western blot assays. 
Fluorescence Microscopy—Cells were grown on 18-mm 
glass coverslips in complete medium for at least 2 days prior 
to fixation. Cells were washed twice with PBS and fixed in 
PBS containing 1% formaldehyde for 1 h at room tempera-
ture, followed by two rinses in PBS. Nonspecific antibody in-
teractions were blocked with PBS containing 0.25% BSA for 
30 min. Alternatively, cells were permeabilized (45) with 
0.05% saponin for 30 min at room temperature after the 
blocking procedure. Cells were incubated with both primary 
and secondary antibodies in PBS containing 0.25% BSA for 
1 h and washed between incubations. Glass coverslips were 
mounted onto glass slides immediately prior to visualization 
using a Nikon Diaphot 300 fluorescence microscope. Images 
were captured with a DXM1200 side-mounted camera oper-
ated by Act-1 software version 2.6.3. 
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Secreted Receptor Constructs—cDNA constructs for the se-
creted ectodomains of both the 315- and 190-HARE were 
produced by deleting the transmembrane and cytoplas-
mic domains, while retaining the V5 and His6 tags. A single 
primer, 5′-GTGACCTTGACCCACACTGGATCCGAAGG-
TAAGCCTATC-3′, was used in individual mutagenic re-
actions with the wild type HARE cDNAs (315-HARE in 
pcDNA5/FRT/V5/His, 190-HARE in pSecTag/FRT/V5/
His) in an Ericomp thermocycler for 18 cycles (94 °C for 30 
s, 63 °C for 30 s, 71 °C for 1 min/plasmid kb) using pfu Ul-
tra. After the reaction, the plasmid was ethanol-precipitated 
and resuspended in 17 μl of H2O, 2 μl of NEB4 buffer, and 
2.5 units of DpnI to cut the template plasmid while retaining 
the intact mutant plasmid. After an overnight incubation at 
37 °C, the digest mix was heated to 95 °C for 10 min, cooled, 
and immediately transformed into TOP10 supercompetent 
E. coli cells. Bacterial cells containing the plasmid of choice 
were screened by a miniprep procedure, and PCR and DNA 
sequencing confirmed the mutation. Plasmids containing the 
desired mutation were used to make stable cell lines, which 
were created and evaluated as described above. 
Soluble HARE Purification—s190-HARE or s315-HARE 
was purified from pooled cell growth media (DMEM con-
taining 8% FBS and 100 μg/ml hygromycin B) via the His6 
tag. To remove particulate matter, conditioned medium (in-
cubated with cells for at least 2 days) was centrifuged at 1500 
rpm for 4 min. Clarified medium was supplemented with the 
following to the indicated final concentrations: 10% glycerol, 
250 mm NaCl, 10 mm imidazole. A 1% volume of 50% slurry 
of Ni2+-charged Sepharose 6 Fast Flow resin (Amersham Bio-
sciences) was added, and the mixture was incubated over-
night at room temperature with gentle rotation. The resin 
was captured in a 25-ml column, washed with 10 column 
volumes of PBS containing 10 mm imidazole, and then 
eluted with 4 column volumes of PBS containing 400 mm 
imidazole. The partially purified HARE was concentrated 
using a 30-kDa molecular mass cut-off concentrator and sep-
arated by SDS-PAGE on a 5% gel. The gel was stained with a 
4% CuCl2 solution to visualize protein bands, and the HARE 
band was cut out of the gel with a clean razor blade, minced, 
and electroeluted overnight in dialysis tubing (35 V, 4 °C) in 
185 mm glycine, 25 mm Tris-HCl, pH 8.5, 0.07% SDS. The fi-
nal purified HARE preparation was concentrated to 0.1–1.0 
mg/ml as above, washed twice with PBS, and stored at –20 
°C until use in subsequent assays. 
ELISAs—All steps were carried out at 37 °C. A set amount 
of HARE protein in Coating Buffer (200 μl) was incubated 
in each well of a Polysorb strip for 2 h. The surface of the 
well was then blocked with TBST supplemented with 2% 
BSA and 0.1% Tween 20 for 1.5 h. After washing, increasing 
concentrations of biotin-HA were incubated for 2 h, washed 
six times with TBST (without protein), incubated for 1 h 
with streptavidin-alkaline phosphatase, washed six times in 
TBST, and finally incubated with p-nitrophenyl phosphate. 
The A405 of the strips were determined each hour for 3 h. 
Cell Surface Biotinylation and Immunoprecipitation—Four 
different 315-HARE clones (17.5, 29, 30, and 36) were grown 
to confluence in T-25 tissue culture flasks. After a 60-min in-
cubation in serum-free medium, the cells were washed twice 
with cold PBS and incubated in the presence or absence of 
0.05% digitonin (45) in PBS for 10 min at 4 °C. The cells were 
then washed twice with cold PBS and treated with 2 mm 
sulfo-NHS-SS-biotin in PBS for 30 min at 4 °C. The biotinyl-
ation reaction was terminated by washing and then incubat-
ing the cells with 100 mm glycine, pH 8.0, in PBS for 20 min 
at 4 °C to quench unreacted sulfo-NHS-SS-biotin. Washed 
cells were then lysed in 0.5% Nonidet P-40 PBS containing 
200 μm phenylmethylsulfonyl fluoride, 1.0 μg/ml pepstatin, 
and 1.0 μg/ml leupeptin for 1 h at 4 °C, and cell lysates were 
cleared by centrifugation at 14,000 × g for 10 min at 4 °C. The 
resulting supernatant was used for immunoprecipitation ex-
periments. Anti-rat HARE mAb-159 (2 μg/ml) was added to 
1.0 ml of supernatant, which was incubated with rotation for 
2 h at 4°C, and immune complexes were then collected with 
20 μl of 250 μg/ml Protein A/G-Plus-agarose overnight at 4 
°C. The resin was washed three times with cold PBS, and the 
pellet was resuspended in 30 μl of 2× Laemmli sample buf-
fer without reducing agent, incubated for 3 min at 90 °C, and 
subjected to SDS-PAGE and Western analysis. 
Results
Two Isoforms of HARE Are Expressed from a Single 315-
HARE cDNA—Results from previous studies showed that 
HARE is a cell surface receptor that clears HA, CS, and ad-
vanced glycation end products from the circulatory and lym-
phatic systems. Studies of HARE or stabilin/FEEL-2 in other 
laboratories focused only on the large isoform, disregarding 
the possibility of a smaller isoform (i.e. the 190-kDa HARE). 
However, we have shown that the smaller isoform of the re-
combinant rat (29) or human HARE (37) is a recycling endo-
cytic receptor specific for HA and multiple CS types that op-
erates via the coated pit endocytosis pathway. To study the 
specificity and function of the large human HARE, we ampli-
fied and cloned the open reading frame from pooled lymph 
node cDNA and inserted the full-size 315-HARE cDNA into 
the expression vector pcDNA5/FRT/V5-His-TOPO. Except 
for the absence of the secretion signal, this is the same vector 
that we used previously to express and characterize the in-
dependent function of the 190-HARE. 
The full-length 315-kDa HARE type I membrane protein 
contains an extracellular domain with four cysteine-rich fas-
ciclin/epidermal growth factor-like domains of unknown 
function, an extracellular LINK domain, a cytoplasmic do-
main, and a single membrane domain (Figure 1A). The 190-
HARE is identical to the C-terminal 1417 amino acids of the 
full-length HARE (Figure 1A), which we previously sug-
gested arises by proteolytic cleavage (29, 37). 
The six cell lines used in this study each contain a single 
315-HARE cDNA integrated at the single correct recombi-
nase-specified site in Flp-In 293 cells, as confirmed by their 
resistance to hygromycin B, lack of β-galactosidase activity, 
and sensitivity to zeocin. The amount of 315-HARE expres-
sion in all six cell lines was only ~12% of that observed for 
recombinant 190-HARE expressed alone in the same cells 
using the same promoter and growth conditions (37). None-
theless, all six cell lines mediated specific HA endocytosis 
over 4 h that was well above the background level of the pa-
rental Flp-In 293 cells or cells transfected with vector alone 
(not shown). 
Unexpectedly, all cell lines expressing the single cDNA en-
coding full-length 315-kDa HARE produced two individual 
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HARE proteins with molecular masses of ~315 and 190 kDa 
as detected in Western blots using an antibody against the 
C-terminal V5 epitope (Figure 1B). The native spleen and 
recombinant 190-HAREs migrated identically in 5% SDS-
PAGE with the 190-kDa species in these 315-HARE cell lines 
(not shown). The HARE expression patterns among all the 
cell lines were virtually identical, and the majority of the 
recombinant protein migrated at ~315 kDa with a lesser 
amount migrating at 190 kDa (Figure 1B). All cell lines pro-
duced approximately the same amount of 315-kDa recep-
tor relative to cellular actin (1.9 ± 0.2 for the six samples in 
Figure 1, B and C) and produced similar ratios of the 315-
kDa to 190-kDa HARE (2.7 ± 0.4 for the experiment in Figure 
1B). The 315/190-HARE ratio was typically 3–4:1 in multiple 
Western analyses using detection by either chemilumines-
cence or alkaline phosphatase. 
Recombinant HARE Appears to Be Folded and Glycosylated 
Correctly and Specifically Binds HA—Although we do not 
know why expression of the recombinant full-length HARE 
was lower than the independently expressed 190-HARE, 
we suspect that overexpression of such a large protein con-
taining 202 cysteines might overwhelm the endoplasmic re-
ticulum systems that facilitate protein folding and disulfide 
bond formation. The two expressed receptors appear to be 
folded correctly based on their reactivity with three anti-rat 
mAbs that cross-react with human HARE (Figure 2) and the 
specific HA binding activity of each recombinant protein in 
ligand blot and cell culture assays. mAbs 30, 154, and 159 de-
tected both the larger and smaller HARE proteins in whole 
cell lysates of 315-HARE-transfected cells (Figure 2, NR). Re-
duction of the proteins with dithiothreitol resulted in detec-
tion by only mAb 159 (Figure 2, R), confirming that mAbs 
30 and 154 recognize conformational (e.g. sulfhydryl-de-
pendent) epitopes, perhaps within the Cys-rich epidermal 
growth factor-like domains that are conserved between rat 
and human HARE proteins. Using SDS-PAGE to resolve 
the two HARE species, we verified that both receptors spe-
cifically bind 125I-HA in a ligand blot assay (Figure 3A). The 
above results demonstrate that the 190-kDa protein pro-
duced by 315-HARE cell lines is a HARE isoform and not an 
artifact of the assays performed. In addition, stable cell lines 
containing the empty vector alone do not show mAb- or HA-
binding bands at these Mr positions (not shown). 
Reduction by dithiothreitol, followed by alkylation to 
block refolding via disulfide bond formation, dramatically 
shifted the migration of the 190-HARE species to apparently 
larger mass (Figure 3B). The decreased migration of the re-
duced 315-HARE through 5% SDS-PAGE was less apparent, 
since migratory shifts in a protein of this size are more diffi-
cult to demonstrate. Also, the rod-like geometry of the non-
reduced and reduced full-length receptor may contribute 
to their similar migration patterns (51). We conclude from 
Western blot and silver stain (not shown) analyses of reduced 
Figure 1. Schematic of the two HARE isoforms and their expression 
in stable cell lines. A, the scheme illustrates the domain organization 
of the 315- and 190-kDa HARE proteins. The four Cys-rich domains 
are 37–39% identical (~50% similar) to each other. Each receptor iso-
form contains one LINK domain, one transmembrane region, and one 
cytoplasmic domain. The arrow indicates the N terminus of the 190-
kDa HARE (Ser1136), which may be the site of cleavage to create this 
isoform. B, in order to assess the cellular ratios of 315- to 190-HARE 
isoforms, cells were scraped from T-25 flasks, washed, and resus-
pended in PBS with 0.5% Nonidet P-40 and protease inhibitors. The 
cell lysates were incubated with rotation at 4 °C for 1 h and centri-
fuged to remove cell debris, and total protein content of each sample 
was quantified using the Bradford assay (46). Lysate protein (20 μg) 
was analyzed by SDS-PAGE and Western blots. The 315-HARE (filled 
arrow) and 190-HARE (open arrow) were detected by chemilumines-
cence using polyclonal anti-V5 antibody. C, the blot was stripped and 
reprobed with anti-actin antibody to allow samples to be normalized to 
cellular protein content. 
Figure 2. Both recombinant human 315- and 190-kDa HARE isoforms 
cross-react with rat anti-HARE mAbs. Whole cell lysates were sub-
jected to reducing (R) or nonreducing (NR) conditions, separated by 
5% SDS-PAGE, and electrotransferred to nitrocellulose as described 
under “Experimental Procedures.” Nitrocellulose was cut into strips 
and blocked with TBST/BSA, and each strip was incubated with 1 μg/
ml mouse IgG or one of the eight indicated mAbs raised against the rat 
175-kDa HARE (28, 33). The 315-kDa HARE (filled arrows) and the 
190-kDa HARE (open arrows) proteins were recognized by mAbs 30, 
154, and 159 in the nonreduced samples, whereas both receptors re-
acted with only mAb 159 when reduced. The anti-V5 lane (far right) 
was a positive control for mAb detection. 
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and nonreduced samples that the recombinant human 315-
HARE is a single polypeptide and not composed of multiple 
subunits linked together by disulfide bonds. 
When the full-length hHARE was treated with endogly-
cosidase F to remove N-linked oligosaccharides, a more pro-
nounced migratory shift was observed (Figure 3C), which was 
similar to that observed previously for the recombinant 190-
HARE and the native rat and human receptor isoforms. Endo-
glycosidase F treatment did not affect 125I-HA binding, reveal-
ing that N-linked glycans are not required for HA binding. 
Due to the low amount of recombinant 190-kDa HARE 
in the 315-HARE stable cell lines, we were not able to ob-
tain enough purified 190-HARE for N-terminal amino acid 
sequencing. However, we purified the 190-HARE from 
a human spleen sample and obtained the sequence NH2-
LLPNLLMRL. Except for the first amino acid, this sequence 
is identical to the presumed sequence for the 190-HARE start-
ing at Ser1136 of the full-length protein. The first Leu in our 
sample may be a sequencing error or a real mutation (poly-
morphism) in the genome of the individual spleen donor. 
Cells Expressing HARE Endocytose and Degrade 125I-HA—
Recombinant HARE encoded by the full-length cDNA is bi-
ologically active, since cells expressing the protein can endo-
cytose HA. Four different cell lines (17.5, 29, 30, and 36) were 
allowed to endocytose 125I-HA with and without competing 
nonlabeled HA over a 26-h period (Figure 4A). Unlike the 
parent Flp-In 293 cells or cells transfected with vector alone, 
315-HARE cells specifically internalized HA. HA uptake in-
creased and reached a steady state accumulation after about 
24 h. In addition to internalization, the Flp-In 293 cells were 
able to deliver HA to lysosomes, where it was degraded (Fig-
ure 4B), presumably by the combined actions of endogenous 
lysosomal hyaluronidases, β-N-acetylglucosaminidase, and 
β-glucuronidase. Unlike the previously described 190-HARE 
cell lines, the 315-HARE clones varied more in their HA en-
docytic rates and degradation. 
We and others showed previously that internalization of 
HARE in primary cell cultures or stable cell lines occurs via 
a clathrin-coated pit pathway (21, 29, 35, 39). To confirm that 
the recombinant 315-kDa HARE mediates endocytosis via 
coated pits, we incubated 315-HARE clone 30 cells with 125I-
HA for 4 h in medium containing increasing amounts of su-
crose (Figure 4C). Under hyperosmotic conditions (e.g. ≥0.4 
m sucrose), receptor-mediated endocytosis decreased by 
>90%, indicating that HA uptake depends on clathrin assem-
bly into coated pits (52–54). 
The s315- and s190-HARE Ectodomains Bind 125I-HA—The 
secreted s315-HARE ectodomain was purified from cell cul-
ture medium via either the His6 tail using nickel-chelate affin-
ity chromatography or anti-V5 immunopurification. Partially 
purified s315-HARE appeared to be folded correctly, since it 
bound HA in the ligand blot assay (Figure 5A), whereas re-
duction nullified HA binding, and deglycosylation did not af-
fect HA binding, which were the same results seen with the 
membrane-bound 315-HARE. Expression and glycosylation 
of the s190 and s315-HARE ectodomains in cell culture were 
virtually identical. In addition, the recognition of the soluble 
receptors by mAbs 30 and 154 was the same as the membrane 
receptors in Western blot or immunoprecipitation assays (not 
shown). Both HARE ectodomains also bound comparable 
amounts of 125I-HA in the ligand blot assay (Figure 5B). 
Since the s315-HARE has HA binding capability compa-
rable with the wild type receptor, we used an ELISA-like as-
say to estimate the HA binding affinity. Purified s315-HARE 
or s190-HARE was plated on Polysorb strips, nonspecific 
binding sites were blocked with BSA, and the strips were in-
cubated with increasing amounts of biotin-HA. Bound bio-
tin-HA was detected with streptavidin-alkaline phosphatase. 
The binding of biotin-HA to either HARE ectodomain was 
almost identical (when normalized to pmol of protein). The 
data were fit as second order binding curves (Figure 6) with 
a calculated Kd value of 9.9 ± 1.2 nm (p < 0.0001) for the s315-
HARE and 20.7 ± 6.4 nm (p = 0.0004) for the s190-HARE. 
These Kd values are very close to the dissociation constant 
Figure 3. The nonreduced 315- and 190-kDa HARE proteins specifi-
cally bind HA. Whole cell lysates from cells stably expressing recom-
binant 315-kDa HARE were subjected to either reduction and then al-
kylation or nonreducing conditions, followed by 5% SDS-PAGE and 
electrotransfer to nitrocellulose membranes. A, a ligand blot (LB) as-
say was first performed by incubating the nitrocellulose with 1 μg/ml 
125I-HA either alone or mixed with a 100-fold excess of unlabeled HA, 
washing, and autoradiography as described under “Experimental Pro-
cedures.” B, following the ligand blot, the nitrocellulose membrane was 
rehydrated in TBST/BSA, and Western blot (WB) analysis was per-
formed using anti-V5 antibody to identify hHARE. C, the 315-HARE 
protein was immunoprecipitated from cell lysates with mAb 30, eluted 
from the resin with 0.1% SDS, and digested overnight with endoglyco-
sidase F. After electrophoresis and electrotransfer to nitrocellulose, the 
blot was subjected to the 125I-HA ligand blot assay followed by West-
ern blot analysis with anti-V5 antibody. 
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 value of 7 nm determined for HA-receptor complexes in cells 
expressing recombinant 190-HARE (37). 
HARE Binds to a Subset of GAGs in Addition to HA—We 
previously reported that other GAGs compete with HA for 
binding to the 190-HARE. Since it is not known how HARE 
binds to its multiple ligands or what domains within the 
protein interact with each ligand, the GAG-binding proper-
ties of the larger 315-kDa HARE may be different from those 
of the smaller HARE. We therefore tested the GAG-bind-
ing and internalization properties of cells expressing the 
315-HARE to discern whether they were different for this 
larger HA-binding receptor. This was tested in endocytosis 
assays in which 190-HARE (clone 14) and 315-HARE (clone 
30) stable cell lines were allowed to endocytose 125I-HA in 
the presence of an excess of different competing GAGs (Fig-
ure 7A). These results showed that the GAG-binding profiles 
are very similar between cells independently expressing the 
190-HARE and cells expressing the 315-HARE (and smaller 
amounts of 190-HARE). The ability of all of the CS types to 
compete for HA uptake indicates that these GAGs bind at or 
near the HA binding site(s) in either HARE ectodomain. 
Thus far, all of our binding experiments have used 125I-
HA and competing nonlabeled GAGs in live cell assays to 
obtain evidence that the other GAGs bind to HARE. Since 
negative results in these indirect assays do not rule out the 
presence of independent binding sites for the other GAGs, 
we developed direct binding assays to determine whether 
Figure 4. Endocytosis and degradation of 125I-HA by cells expressing 
HARE. Four 315-HARE cell lines (clone 30 (▼), clone 29 (●), clone 36 
(■), and clone 17.5 (♦) were plated in 24-well plates and grown to conflu-
ence. A, after a 60-min incubation in serum-free medium, the cells were 
washed with 1 ml of HBSS and allowed to endocytose 1.5 μg/ml 125I-HA 
in DMEM supplemented with 0.05% BSA, with or without 150 μg/ml un-
labeled HA. At the noted times, medium was aspirated, and the well was 
washed three times with 1 ml of HBSS. The cells were lysed in 0.5 ml of 
0.3 n NaOH, and radioactivity and protein were determined. The values 
shown are the average of duplicates (typically within 10%) for specific 
cell-associated cpm/μg of protein: total uptake (no excess HA) minus 
the nonspecific uptake (with excess unlabeled HA). Specific uptake and 
degradation values, which varied depending on the cell line and time 
point, were 77–87 and 62–87%, respectively. B, cell-associated degra-
dation of 125I-HA was determined at the noted times by a cetylpyridinium 
chloride precipitation assay, as described under “Experimental Proce-
dures,” using a portion of the neutralized cell lysate from the samples in 
A. Degradation values are the average of duplicates. C, 315-HARE cells 
mediate HA internalization by a clathrin-coated pit pathway. 315-HARE 
clone 30 cells were incubated in medium with 1 μg/ml 125I-HA with (to 
assess nonspecific uptake) or without (to assess total uptake) a 100-fold 
excess of unlabeled HA and increasing concentrations of sucrose, as in-
dicated. A stock 1.2 m sucrose solution was made in DMEM-BSA and 
diluted in DMEM-BSA to give the final concentrations indicated. Prior to 
the experiment, cells were incubated at 37 °C in DMEM-BSA for 1 h and 
then DMEM-BSA/sucrose for an additional 15 min. At time 0, the 125I-
HA mixes in DMEM-BSA/sucrose were added, and after 4 h the cells 
were washed, and protein content, radioactivity, and specific HA uptake 
were determined as described under “Experimental Procedures.” Spe-
cific 125I-HA endocytosis without sucrose was 70%. Specific cpm/μg of 
protein values for endocytosis are means ± S.D. (n = 3). 
Figure 5. The secreted 315-kDa HARE ectodomain is glycosylated 
and functional. A, the s315-HARE was purified by Ni2+ affinity chro-
matography and reduced with dithiothreitol or deglycosylated with en-
doglycosidase F treatment as described under “Experimental Pro-
cedures.” The deglycosylated receptor retains HA binding activity as 
seen in the ligand blot (LB) assay, in contrast to the reduced recep-
tor, which does not bind 125I-HA. Following the ligand blot, the same 
membrane was subjected to Western blot (WB) analysis using anti-V5 
antibody. B, the s190-HARE and s315-HARE demonstrate compara-
ble 125I-HA-binding activities in the ligand blot assay. A ligand blot as-
say was performed with increasing amounts of purified s190-HARE or 
s315-HARE protein after SDS-PAGE and electrotransfer. 
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other GAGs can bind HARE. To test this possibility, we pre-
pared a panel of eight biotin-GAGs (i.e. chondroitin, CS-A, 
CS-B, CS-C, CS-D, CS-E, HA, and HS) and assessed the GAG 
binding to HARE using a ligand blot procedure similar to 
that described above for 125I-HA (Figure 7B). In this experi-
ment, the s315-HARE was purified by Ni2+-chelate chroma-
tography followed by 5% SDS-PAGE, blotted to nitrocel-
lulose, and incubated with biotin-GAG with or without an 
excess of the same nonbiotinylated GAG to determine non-
specific binding. Binding of the biotin-GAG was then de-
tected using 125I-streptavidin and autoradiography. The re-
sults showed specific binding of the s315-HARE with CS-C, 
CS-D, CS-E, and HA, suggesting that HARE is a clearance 
receptor for multiple GAGs (Figure 7B). Biotin-HS did not 
bind to the s315-HARE. We know from other experiments 
(and longer exposure times of this experiment) that CS-B 
and chondroitin also bind to HARE but with a lower affinity 
that has yet to be measured (not shown). 
A Majority of HARE Resides on Intracellular Vesicles—Since 
endocytic recycling receptors are found on the cell surface 
and in multiple early endosomal compartments along their 
intracellular itinerary, we wanted to determine the distri-
bution of HARE between surface and intracellular compart-
ments. The 190-HARE, for example, is distributed roughly 
equally, with ~50% on the cell surface (37). This is similar 
to the rat small HARE isoform stably expressed in SK-Hep1 
cells, which co-localized with early endocytic markers, such 
as clathrin, but not later endosomes or lysosomes (29). An ini-
tial assessment of receptor localization was performed using 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fluorescence microscopy in which cells were either permea-
bilized with 0.05% saponin (Figure 8A) or intact (Figure 8B), 
and the fixed cells were probed with mAb-30 against the 
315- and 190-HARE proteins. The permeabilized cells con-
tained numerous bright intracellular vesicles with a faint 
ring of staining representing the cell surface. In contrast, 
nonpermeabilized cells showed only distinct perimeter fluo-
rescence, indicating surface expression (Figure 8B). The fluo-
rescence output from a field of permeabilized cells was ~4–5 
times greater than a field of nonpermeabilized cells, confirm-
ing that most HARE is intracellular. 
Next, we used a biotin-labeling technique to determine 
the ratio of internal to surface receptor, because differences 
in this ratio could explain the clonal differences in endocy-
Figure 6. The s315- and s190-HARE ectodomains bind HA with high 
affinity. The s315-HARE and s190-HARE ectodomains were puri-
fied by affinity chromatography and electroelution, plated on Poly-
sorb strips in duplicate (0.5 μg/well), and allowed to bind increasing 
amounts of biotin-HA as described under “Experimental Procedures.” 
After washing, bound biotin-HA was detected with streptavidin-alkaline 
phosphatase using p-nitrophenyl phosphate as substrate, and A405 
values were normalized per pmol of protein plated. The lines are re-
gression analyses for s315-HARE (solid line, open circles) and s190-
HARE (dotted line, closed circles) data calculated using the ligand 
binding curve-fitting and analysis of variance functions of SigmaPlot 
version 10.0. The Kd values for biotin-HA binding to s190- and s315-
HARE under these experimental conditions were 20.7 ± 6.4 (S.E.) nm 
(p = 0.0004) and 9.9 ± 1.2 (S.E.) nm (p < 0.0001), respectively. 
Figure 7. 315- and 190-HARE cell lines display similar patterns for 
glycosaminoglycan competition of HA endocytosis. A, 315-HARE 
clone 30 and 190-HARE clone 41 cells were plated in 12-well plates 
and grown to confluence. After a 1-h incubation in serum-free medium, 
the cells were washed with 2 ml of HBSS and allowed to endocytose 
1.5 μg/ml 125I-HA for 4 h at 37 °C in DMEM supplemented with 0.05% 
BSA with or without 30 μg/ml of the noted GAG. The medium was as-
pirated, the well was washed three times with 2 ml of HBSS, and the 
cells were lysed in 1 ml of 0.3 n NaOH. Radioactivity and protein per 
sample were determined. The data are expressed as a percentage of 
the radioactivity in cells with no other GAG addition. The mean ± S.D. 
(n = 6) of duplicates from three separate experiments is shown. B, di-
rect binding of a GAG was assessed by a ligand blot assay in which 
the indicated biotin-GAG was incubated alone or with a 4-fold excess 
of unlabeled GAG. After washing the membrane strips containing the 
protein-GAG complex, the biotin-GAG remaining was detected by au-
toradiography after incubation with 2.5 μg/ml 125I-Streptavidin. CS-
C, CS-D, CS-E, and HA bound with HARE with the highest affinity, 
whereas CS-B and chondroitin (Chon) bound with a low affinity. No 
binding was detected with CS-A or HS. The negative control (far right 
lane, top) containing the same amount of s315-HARE was not treated 
with any biotin-GAG but was treated with 125I-streptavidin. 
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tosis of HA among cell lines. Cells from four different 315-
HARE cell lines were incubated with biotinylation reagent 
on ice to prevent constitutive endocytosis and without (non-
permeabilized) or with (permeabilized) 0.05% digitonin to 
allow perfusion of the biotinylation reagent to the cell inte-
rior. Total HARE was then immunoprecipitated from cell ly-
sates, and Western analysis was performed to compare the 
amount of biotinylated HARE (using streptavidin-horserad-
ish peroxidase) and total HARE (using anti-V5 antibody). 
The results demonstrated that a majority of the 190-HARE 
and 315-HARE in all four clones resides on the interior of the 
cell. Cells not treated with digitonin had only their cell sur-
face receptors biotinylated, and the ratio of those receptors 
compared with the total receptor content (i.e. anti-V5 stain-
ing) was low (Figure 9, A–D, light and dark gray bars). In con-
trast, most of the HARE in permeabilized cells was biotinyl-
ated, and the ratio of biotin-HARE to V5 staining was quite 
high, indicating a much greater receptor content inside cells 
relative to the surface (Figure 9, A–D, open and solid bars). 
Based on these biotin-labeling and the preceding fluores-
cence experiments, we estimate that only about 5–10% of the 
total cellular HARE, for either isoform, is at the cell surface. 
Discussion
HARE, which has also been named stabilin-2, Feel-2, and 
Fex-2 by other laboratories, is the primary receptor for the 
clearance of HA and probably CS from the circulatory and 
lymphatic systems. HARE binds not only HA but also other 
GAGs, particularly the CS types, with high specificity. HA, 
free CS chains, and probably CS proteoglycan fragments, 
all of which continuously flow from tissue ECMs, first en-
ter the lymphatic system and encounter the endocytic, recy-
cling HARE in the lymph nodes, where most of these ECM 
 
 
 
 
 
 
 
 
 
 
 
components are degraded. This normal GAG turnover pro-
cess might be accelerated in wound healing, injury, growth, 
and other disease states, including some cancers. Most of the 
high molecular mass (>106-Da) HA and, presumably, the 
other CS-type GAGs are cleared in the lymph nodes, and the 
remaining GAGs that enter the blood stream are cleared by 
liver sinusoidal endothelium-associated HARE. The activity 
of this GAG clearance system was first observed in experi-
ments using animal models to study HA catabolism (17, 18, 
34, 55). In addition to its scavenger activity, HARE located in 
the spleen, which is not a clearance organ, may play an im-
portant yet unknown role in immune system function. 
In this report, we note that human HARE is expressed as 
two isoforms that are encoded from the same cDNA (i.e. an 
mRNA not subject to alternate splicing). The 190- and 315-
kDa isoforms are recognized by the same subset of anti-rat 
HARE mAbs, and both soluble ectodomains bind HA to the 
same extent and with almost the same affinity. Both HARE 
isoforms also recognize multiple CS types as well as HA. 
We know that cells expressing only the 190-kDa isoform can 
function in the absence of the 315-kDa isoform to bind and 
internalize HA and other GAGs (37). When both the 315- and 
190-kDa HARE are present in the same cells within a tissue, 
Figure 8. Cellular localization of HARE. 315-HARE clone 30 cells 
were grown on glass coverslips, fixed, and treated either with (A) or 
without (B) saponin as described in Reference 45 and under “Exper-
imental Procedures.” Anti-HARE mAb 30 followed by rhodamine-la-
beled anti-mouse secondary antibody was used to detect the recep-
tor. Detergent-permeabilized cells were about 4–5 times brighter than 
the untreated cells, indicating that most of the receptor resides in in-
tracellular membrane vesicles. Images of the cells were taken in color, 
converted to grayscale, and then black-and-white-inverted to visual-
ize more clearly the cellular details seen in the color images. The cells 
shown were representative of all of the cells in a typical field at ×600 
magnification. Bars, 10 μm. 
Figure 9. Biotinylation analysis of the cellular distribution of the two 
HARE isoforms in 315-HARE cell lines. 315-HARE cell lines 17.5 
(A), 29 (B), 30 (C), and 36 (D) were plated in tissue culture flasks and 
grown to confluence. Cell surface or total cellular receptors were bio-
tinylated using 2 mm sulfo-NHS-SS-biotin for 10 min at 4 °C, respec-
tively, in the absence (not permeabilized) or presence (permeabilized) 
of 0.05% digitonin (45). Cells were solubilized with 0.5% Nonidet P-40 
plus protease inhibitors and then processed for immunoprecipitation 
with mAb 159 and analysis by SDS-PAGE as described under “Exper-
imental Procedures.” After electrophoresis, the proteins were electro-
transferred to nitrocellulose and probed with streptavidin-horseradish 
peroxidase conjugate, and the same blots were then stripped and rep-
robed with anti-V5 antibody. The blots were scanned, and the digital 
data were expressed as the average (n = 4) ratio of streptavidin/V5 de-
tection (band densities). Shown are 190-kDa HARE (unpermeabilized 
(light gray bar) and permeabilized (white bar)) and 315-kDa HARE (un-
permeabilized (dark gray bar) and permeabilized (black bar)). 
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we do not yet know whether they can function as indepen-
dent receptors, as heterooligomeric complexes, or as both. 
Based on our experiments with the recombinant HARE 
isoforms expressed in stable cell cultures, either together or 
the 190-HARE alone, it seems that the biological activities of 
these two receptors are remarkably similar. Both HARE iso-
forms contain the same LINK domain and the two C-termi-
nal Cys-rich domains (Figure 1A). The larger isoform has the 
additional two N-terminal Cys-rich domains. These four do-
mains are highly conserved, especially their Cys alignments, 
which indicates that their disulfide bond pattern and over-
all folding are essentially identical. Although the function of 
these Cys-rich domains is not known, it is tempting to spec-
ulate that they are involved in GAG binding, perhaps with 
multiple similar binding sites in each domain. Studies are 
in progress to test this possibility. Both HARE isoforms also 
contain the same cytoplasmic domain for potential intracel-
lular signaling (e.g. endocytic trafficking). 
Thus far, it has not been possible to study the activity of 
the membrane-bound 315-HARE independently of the 190-
kDa receptor, since proteolytic cleavage appears to be the 
normal processing pathway for the full-length protein in 293 
and other cells (e.g. CHO), as it appears to be in vivo. Despite 
the consequent complication of not being able to characterize 
the GAG binding and endocytic ability of the 315-kDa HARE 
by itself in live cells, we were able to demonstrate that the 
soluble ectodomain of the 315-HARE binds directly to CS-C, 
CS-D, and CS-E in addition to HA. We also detected a lower 
level of s315-HARE binding to CS-B and chondroitin, but the 
sensitivity of the ligand blot assay may not be sufficient to 
quantify these interactions. We are currently developing al-
ternative assays to address this issue. 
The only inconsistency we have observed in the GAG-
binding activity of HARE occurred with CS-A. In live cell as-
says, CS-A competes very effectively with labeled HA (20, 
23, 29, 36, 37); however, we could not detect a CS-A-HARE 
interaction by ligand blot assays, and we obtained similar 
sporadic binding results in ELISA-like assays (not shown). 
The binding activity of CS-A may be sensitive to the condi-
tions of our in vitro assays, or the affinity may be too low to 
retain a good signal with the washing protocol in these as-
says. We are currently working to optimize the level of de-
tection with these assays as well as testing whether the 190-
HARE and 315-HARE have different GAG binding profiles 
due to the additional protein domains of the larger isoform. 
Expression of the full-length 315-HARE cDNA produces 
two protein products of different size but similar function. 
The processing of the 315-HARE appears to be a tightly reg-
ulated process, since the ratio of 315- to 190-HARE was con-
sistently ~3–4:1 in multiple experiments with the six cell 
lines used here. Earlier results also demonstrated a consis-
tent ratio of the two isoforms in rat liver or human spleen 
and the possibility that isoform ratios might differ between 
tissues (30, 33). From our protein sequencing data, the 190-
HARE purified from human spleen begins at Ser1136. This N-
terminal region does not contain a consensus sequence or 
motif for known proteases, and the biological implications of 
such an activity are unknown at this time. A goal for future 
studies is to prevent processing of the 315-HARE, by use 
of inhibitors or mutagenesis, in order to study the cellular 
function of this larger isoform in the absence of the 190-kDa 
HARE. In ongoing studies, mutagenesis of a possible adja-
cent furin-like site (KK1131 to AA1131) did not eliminate the 
proteolytic processing in 293 cells. Similarly, studies with a 
variety of commonly used protease inhibitors (e.g. cathepsin 
L, GM6001, EDTA, E-64, aprotinin) failed to identify a po-
tential protease. We are currently investigating how proteo-
lytic cleavage of HARE occurs, what protease is involved, or 
whether HARE itself might be autocatalytic. 
Observance of the smaller HARE isoform is not unique 
to our laboratory. A report on murine stabilin-2 and human 
stabilin-1 provided evidence that human stabilin-2/HARE is 
processed to generate the smaller isoform, although the au-
thors did not discuss its presence or consider it relevant (39). 
The highly similar protein stabilin-1 also has a smaller iso-
form of about 140 kDa (56; E. N. Harris, unpublished obser-
vations). Potentially, the smaller isoforms of both stabilin-1 
and HARE may have different ligand-binding profiles or a 
different subset of interacting effector molecules than their 
full-length counterparts. 
Unlike the large native rat liver HARE isoform, which 
contains two large disulfide-bonded subunits of 220 and 250 
kDa (33), the recombinant 315-kDa human HARE is a single 
polypeptide. By Western analysis, the 315-kDa protein band 
did not decrease in size after reduction with dithiothreitol, 
and multiple bands were not detected. Reduction of immu-
noaffinity-purified 315-HARE produced a single band de-
tected by silver staining. In previous studies with purified 
315-HARE from human spleen, we found that this isoform 
contained two large disulfide-bonded subunits. Although 
it is possible that Flp-In 293 cells do not have the capability 
of sinusoidal endothelial cells to post-translationally mod-
ify HARE in the same fashion, in more recent experiments 
with fresher spleen tissue, we did not find multiple subunits 
in the large HARE isoform. It thus appears likely that vari-
able extraction or storage conditions influence nonspecific 
cleavage of the large protein isolated from tissues. Therefore, 
we presently believe that each human HARE isoform is com-
posed of only one type of polypeptide subunit. These results 
do not exclude the possible presence of nondisulfide-bonded 
HARE homo-oligomers or hetero-oligomers, as noted above. 
The expression level of the recombinant 190-HARE in ear-
lier studies (37) was 8–10-fold higher than HARE expression 
in any of the 315-kDa HARE cell lines. Since the same cyto-
megalovirus promoter drives expression of either HARE 
isoform, we initially thought there might be a difference in 
translation efficiency related to the use of two different sig-
nal sequences. To test this, we put the 315-HARE-encoding 
cDNA, without the native signal sequence, into the pSecTag 
vector containing the Ig-κ chain signal sequence. This is the 
same signal sequence used to express the 190-HARE cDNA 
(37). The change in signal sequences did not make any dif-
ference in 315-HARE expression (not shown), indicating that 
lower expression is probably a protein folding or trafficking 
issue rather than a difference in transcription or translation. 
The 315-HARE has 202 Cys residues, compared with 104 
for the 190-HARE, and may simply be much more difficult to 
fold and align correctly for disulfide bond formation. Thus, 
a higher fraction of the 315-HARE protein may be misfolded 
and degraded in the endoplasmic reticulum, compared with 
the 190-HARE. The lower expression of 315-HARE may also 
account for the greater variability in HA endocytic activity 
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among the six cell lines expressing the 315-HARE. This vari-
ability may seem surprising given the single uniform inser-
tion site of the HARE cDNA in Flp-In 293 cells. However, 
the background genotype will not be identical for any cloned 
cell lines, due to random mutations in other genes. Endocy-
tosis and degradation rates may be sensitive to changes in 
hundreds of different proteins involved in coated pit cycling, 
receptor recycling, endosomal, lysosomal, and other intracel-
lular trafficking pathways. Since the signal (i.e. HARE-medi-
ated HA uptake) is lower, such mutations may have more 
noticeable inhibitory effects. 
The human HARE LINK domain is 50% identical (65% 
similar) to the Gallus gallus (chicken) TSG-6 LINK domain 
and 26% identical (44% similar) to the human CD44 LINK 
domain. The LINK domain in HARE is a primary candidate 
for an HA-binding domain, although we do not yet know if 
the epidermal growth factor-like Cys-rich domains facilitate 
binding to HA or to some of the other CS types. The LINK 
domains from HARE, CD44, and TSG-6 contain four highly 
conserved cysteines, which may be required for proper fold-
ing to facilitate HA binding. Based on structural studies and 
computer modeling, most of the LINK amino acids involved 
with HA binding are Tyr (57). Since the results in Figures 
5B and 6 show that the HA-binding ability of the s190- and 
s315-HARE are essentially the same, the common LINK do-
main could be responsible for HA binding. Preliminary re-
sults show that HA endocytosis by cells stably expressing a 
190-HARE LINK-deletion variant is inhibited greatly com-
pared with wild type, but is not eliminated. Currently, we 
are investigating whether the HARE LINK domain binds to 
HA or CS and if potentially key amino acids identified by 
NMR comparison studies of LINK modules are involved. 
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